NIACIN
HYPERCHOLESTEROLEMIA·+6
GOOD NEIGHBOR
Indication
High density lipoprotein deficiency
High density lipoprotein deficiency (hypoalphalipoproteinemia) is a lipid metabolism disorder characterized by abnormally low circulating levels of high-density lipoprotein cholesterol (HDL-C). Read more about High density lipoprotein deficiency
30 drugs 29 manufacturers
Drugs that treat it
Common High density lipoprotein deficiency therapies.
NIACIN
NIACIN/NIACINAMIDE (VITAMIN B-3)·HYPERCHOLESTEROLEMIA·+6
TIME-CAP LABS
NIACIN
NIACIN/NIACINAMIDE (VITAMIN B-3)·HYPERCHOLESTEROLEMIA·+6
NAT'L VIT. CO.
SLO-NIACIN (niacin)
HYPERCHOLESTEROLEMIA·+6
Upsher-Smith Laboratories
NIACIN
NIACIN/NIACINAMIDE (VITAMIN B-3)·HYPERCHOLESTEROLEMIA·+6
MAGNO-HUMPHRIES
NIACIN
HYPERCHOLESTEROLEMIA·+6
BERGEN BRUNSWIG
NIACIN
HYPERCHOLESTEROLEMIA·+6
GOOD NEIGHBOR
NIACIN
HYPERCHOLESTEROLEMIA·+6
HEALTH MART
NIACIN
HYPERCHOLESTEROLEMIA·+6
SUNMARK
Filter & compare in the drug finder →Opens the drug finder with High density lipoprotein deficiency preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonHigh density lipoprotein deficiency (hypoalphalipoproteinemia) is a lipid metabolism disorder characterized by abnormally low circulating levels of high-density lipoprotein cholesterol (HDL-C).
Primarily affecting the cardiovascular system, this metabolic state impairs reverse cholesterol transport, significantly increasing the risk of accelerated atherosclerosis and premature coronary artery disease.
It may occur as an acquired condition secondary to insulin resistance, obesity, smoking, or medications, or arise as a primary genetic disorder caused by mutations in genes such as *ABCA1*, *APOA1*, or *LCAT* (as seen in familial HDL deficiency, Tangier disease, and lecithin-cholesterol acyltransferase deficiency).
Depending on the underlying genetic etiology, defining clinical features range from isolated, marked reductions in serum HDL-C to systemic lipid accumulation manifesting as corneal clouding, hepatosplenomegaly, peripheral neuropathy, and tendon or cutaneous xanthomas.
- medlineplus.gov
High density lipoprotein deficiency (hypoalphalipoproteinemia) is a lipid metabolism disorder characterized by abnormally low circulating levels of high-density lipoprotein cholesterol (HDL-C) Primarily affecting the cardiovascular system, this metabolic state impairs reverse cholesterol transport, significantly increasing the risk of accelerated atherosclerosis and premature coronary artery disease It may occur as an acquired condition secondary to insulin resistance, obesity, smoking, or medic...
- nih.gov
High density lipoprotein deficiency (hypoalphalipoproteinemia) is a lipid metabolism disorder characterized by abnormally low circulating levels of high-density lipoprotein cholesterol (HDL-C) Primarily affecting the cardiovascular system, this metabolic state impairs reverse cholesterol transport, significantly increasing the risk of accelerated atherosclerosis and premature coronary artery disease It may occur as an acquired condition secondary to insulin resistance, obesity, smoking, or medic...
- nih.gov
It may occur as an acquired condition secondary to insulin resistance, obesity, smoking, or medications, or arise as a primary genetic disorder caused by mutations in genes such as *ABCA1*, *APOA1*, or *LCAT* (as seen in familial HDL deficiency, Tangier disease, and lecithin-cholesterol acyltransferase deficiency)
Personalize your experience
Follow High density lipoprotein deficiency and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.